TICKERNERD
Menu
GOSSGOSSHealthcare · Biotechnology

GOSS Stock Forecast: Gossamer Bio, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$0.17
+0.46% on the day

The 7 Wall Street analysts covering Gossamer Bio, Inc. hold a median 12-month price target of $1 — +475.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 2 Sept 2026 — in the upper half.

Market cap
$84.4M
Ticker Nerd rank
59 / 100
Median analyst target
$1.00
Analysts covering
7
Revenue$17.0M+71.5% y/y
Operating income−$44.9M
Net income−$46.7M
Free cash flow−$38.7M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.2%
1M
−0.1%
YTD
−94.4%
1Y
−93.3%
From 52W high
−95.4%
From 52W low
+27.8%
$0.14
$3.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GOSS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Gossamer Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
78
Size
77
Issuance
63
Growth
60
Volatility
59
Value
58
Accruals
56
Quality
27
Momentum
8

Revisions (78): Analysts have, on balance, been raising their forecasts.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GOSS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GOSS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26GOSSHigh $4.00Median $1.00Low $0.28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
3 Buy3 Hold1 Sell
Low $0.28Median $1.00High $4.00

The green dot is the last close — the median target sits +475.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Piper SandlerMaintainsOverweight$15 → $4.00
28 July 2026Leerink PartnersUpgradeOutperform$1.00
28 July 2026Leerink PartnersUpgradeOutperform—
27 July 2026HC Wainwright & Co.ReiteratesBuy$2.00
27 July 2026HC Wainwright & Co.ReiteratesBuy—
25 June 2026HC Wainwright & Co.MaintainsBuy$5.00 → $2.00
25 June 2026HC Wainwright & Co.MaintainsBuy—
26 May 2026HC Wainwright & Co.ReiteratesBuy—
19 May 2026BarclaysMaintainsUnderweight—
23 Mar 2026Cantor FitzgeraldDowngradeNeutral—
6 Mar 2026HC Wainwright & Co.MaintainsBuy—
5 Mar 2026OppenheimerMaintainsOutperform—
24 Feb 2026BarclaysDowngradeUnderweight—
24 Feb 2026Leerink PartnersDowngradeMarket Perform—
24 Feb 2026WedbushDowngradeNeutral—
28 Jan 2026BarclaysInitiatesOverweight—
22 Jan 2026HC Wainwright & Co.ReiteratesBuy—
11 Sept 2025Cantor FitzgeraldReiteratesOverweight—
10 Sept 2025UBSUpgradeBuy—
6 Aug 2025WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GOSS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GOSS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Gossamer Bio, Inc. returned −93.3% against +21.4% for the S&P 500, dividends included.

GOSS vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26GOSSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GOSS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Gossamer Bio, Inc. (GOSS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
1.6×

Cheaper than 59% of US stocks

Price / book
−0.2×

Cheaper than 94% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−19.6%

Higher than 11% of US stocks

Earnings growth (YoY)
71.5%

Higher than 80% of US stocks

Gross margin
—
Operating margin
−282.2%

Higher than 9% of US stocks

Net margin
−235.0%

Higher than 2% of US stocks

Returns & dividend
Return on equity
138.8%

Higher than 97% of US stocks

Return on assets
−62.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Gossamer Bio, Inc. (GOSS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Gossamer Bio, Inc. has a market value of $84.4M and an enterprise value of $67.5M.

  • Revenue in the twelve months to 31 Mar 2026: $55.5M. The latest quarter shrank 19.6% year on year.

  • Net income over the same four quarters: −$180.4M, a −324.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.79.

  • Free cash flow in the twelve months to 31 Mar 2026: −$170.3M, after $53K of capital spending.

  • Shares outstanding: 234.7M.

  • Trailing P/E: −0.2×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Gossamer Bio, Inc. employs 161 people — $345K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

GOSS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GOSSGossamer Bio, Inc.$84.4M
59
DWTXDogwood Therapeutics, Inc.$84.3M
41
MAIAMAIA Biotechnology, Inc.$83.1M
22
KLRSKalaris Therapeutics, Inc.$81.8M
25
CRDFCardiff Oncology, Inc.$81.7M
44
ACETAdicet Bio, Inc.$88.7M
43
YARWYarrow Bioscience, Inc.$80.0M
62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Gossamer Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GOSS news & analysis

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Business Wire · 21 Aug 2026positive

Gossamer Bio announced a structured private placement of up to $250 million, including $150 million of committed capital, through a securities purchase agreement with new and existing institutional investors. The company stated the funds are intended to support seralutinib through potential FDA approval for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Why it matters — A Gossamer Bio watcher would care because this financing provides committed capital to fund development of seralutinib, its lead product candidate, through a potential FDA approval milestone.

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

Gossamer Bio reported a second-quarter net loss of $0.20 per share, wider than the $0.10 per-share loss anticipated by the Zacks Consensus Estimate and greater than the $0.17 per-share loss posted a year earlier. The headline notes the company topped revenue estimates for the quarter.

Why it matters — GOSS watchers would track this report because the quarterly loss came in wider than analyst expectations, signaling how the company is performing versus consensus forecasts.

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Business Wire · 13 Aug 2026neutral

Gossamer Bio, a clinical-stage biopharmaceutical company developing seralutinib for PAH and PH-ILD, announced its financial results for the second quarter ended June 30, 2026, and provided a business update. The company noted it has worked to strengthen the business.

Why it matters — Gossamer watchers would care because the quarterly financial results and business update provide insight into the company's operational progress and financial position as it advances seralutinib.

This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Benzinga · 28 July 2026neutral

The article notes that top Wall Street analysts changed their outlook on several companies, including an upgrade for Honeywell from a previously bearish analyst. No specific mention is made of Gossamer Bio.

Why it matters — While the article does not mention Gossamer Bio, it signals a broader trend of analyst rating changes that may also affect sentiment in the biotech sector where GOSS operates.

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

Benzinga · 27 July 2026positive

Gossamer Bio is preparing to submit a New Drug Application (NDA) for its lead candidate, seralutinib, in September 2026, following a pre-NDA Type B meeting with the FDA. The company's stock is trading higher on the news.

Why it matters — A GOSS watcher would care because a confirmed NDA submission timeline and positive FDA interaction represent a key regulatory milestone for the company's lead pipeline candidate.

FAQ

Frequently asked questions about GOSS stock

What is the GOSS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Gossamer Bio, Inc. have a median 12-month price target of $1, with estimates ranging from $0.28 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GOSS stock a buy right now?

Of the 7 analysts covering Gossamer Bio, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gossamer Bio, Inc. 59 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GOSS?

As at 2 Sept 2026, Gossamer Bio, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).

Will GOSS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +475.4% from the last close, and Ticker Nerd's factor model ranks Gossamer Bio, Inc. 59 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GOSS stock forecast for 2030?

No analyst covering Gossamer Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GOSS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.28 to $4 over the next 12 months.

How has GOSS stock performed over the past year?

Gossamer Bio, Inc. returned -93.3% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gossamer Bio, Inc. do?

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious cardiopulmonary and immune-mediated diseases.

What is the latest news on GOSS?

The most recent item we track (Business Wire, 21 Aug 2026): "Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval". Gossamer Bio announced a structured private placement of up to $250 million, including $150 million of committed capital, through a securities purchase agreement with new and existing institutional investors. The company stated the funds are intended to support seralutinib through potential FDA approval for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Company

About Gossamer Bio, Inc.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious cardiopulmonary and immune-mediated diseases. Its lead program is seralutinib, an investigational inhaled therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company also maintains a broader research pipeline that includes additional candidates across immunology, inflammation, and oncology, reflecting a focus on complex diseases with limited treatment options. Gossamer Bio works to advance its programs through clinical development and partnerships, positioning itself as a specialized biotechnology company centered on rare and chronic conditions. Headquartered in San Diego, California, Gossamer Bio serves as a development-stage player in the biopharmaceutical market.

CEO Mr. Faheem Hasnain · 161 employees · United States · https://www.gossamerbio.com